IL-17A & IL-17F
IL-17A & IL-17F Molekülinformation
| Englischer Name | Interleukin-17F | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 5 | Target-Alias | Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1 |
| Höchste Forschungs- und Entwicklungsphase | NDA/BLA | ||
| Englischer Name | Interleukin-17F |
| Target-Alias | Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 5 |
| Höchste Forschungs- und Entwicklungsphase | NDA/BLA |
IL-17A & IL-17F Produktliste
- Attribut
Protein (3)
- Produktbibliothek
Online (3)
- Spezies
Human (2)Mouse (1)
- Etikett
His Tag & Avi Tag (1)His Tag & Strep Tag (1)His Tag (1)
- Marker
Biotin-labeled (1)Unconjugated (2)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, low endotoxin (MALS verified) |  |  |  |  In den Warenkorb legen | |
| Human | HEK293 | Biotinylated Human IL-17A&IL-17F Protein, Avitag™,His Tag |  | | | In den Warenkorb legen | |
 Mouse | HEK293 | Mouse IL-17A&IL-17F Heterodimer Protein, His Tag (MALS verified) |  | | In den Warenkorb legen |
Gesamtmenge3
- 1
IL-17A & IL-17F Molekülhintergrund
Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
IL-17A & IL-17F Molekülalias
IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,Interleukin-17F,Cytokine ML-1,IL17A＆IL17F
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| ORKA-002 | ORKA-002; PR-029; ORKA-021 | Phase 2 Clinical | Paragon Therapeutics Inc | Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| PN-881 | PN-881 | Phase 1 Clinical | Protagonist Therapeutics Inc | Dermatitis; Psoriasis | Details |
| HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation